²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
about
Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.PET Imaging in Patients with Meningioma - Report of the RANO/PET Group.Somatostatin receptor based imaging and radionuclide therapy.Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotateA fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrierCombination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals.Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine.In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer.α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.Radionuclide Therapy for Neuroendocrine Tumors.Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.Radiotheranostics in Cancer Diagnosis and Management.New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.Preclinical Optimization of Antibody-based Radiopharmaceuticals for Cancer Imaging and Radionuclide Therapy - Model, Vector, and Radionuclide Selection.Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.Interventional Molecular Imaging.Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy.First Results and Experience with PRRT in South Africa.Radium and other alpha emitters in prostate cancerEfficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
P2860
Q30828860-5375E20E-CB0D-4959-8696-441997DCEA47Q34682187-F8D758B1-1798-497C-9FDE-90CB2E653A20Q35296661-022E7945-E85B-4BCE-8225-CABE05B8E57BQ36484229-ADDBE282-0AA1-4D1B-BCE3-6B70F6BCD5A3Q36522639-CAC43E39-2F28-4DC6-8A68-D75017161577Q37281138-6EDEB81E-95D3-4500-973E-7FDBE02719FBQ37427273-9B84B92E-F202-4F72-B041-84E32E6E73B0Q38696649-9CDBF3F5-BC18-4031-BEF2-7BFB0B7324DAQ38712008-0BE04E13-87AD-45DB-A132-62A4D3A39B22Q38715106-ECF5F9EC-0500-4396-9F1B-74E6E97877A4Q38909078-4750C780-5123-4DDF-85D4-1155CC7A7332Q39016753-9D79ACA0-7557-4854-A2EE-B5ED493231CAQ39144880-DF243E74-88E5-4033-99D5-38CDFC5A3A04Q39697612-930FD75E-53A1-4982-8CCD-BCF397D41A26Q41475179-5FA6A4C4-9529-4FCA-BCE4-4906F56BEAD7Q41856358-21F30038-A6B4-495D-977C-F35866D7B242Q47107463-30A61B71-7163-4AC6-A180-53CD4875F334Q47719762-0E7D2A59-C699-4B99-9844-51E82721E549Q47934716-804D9F38-7813-47A5-848E-266E052AA12DQ48089417-EACE0093-EA12-422E-868E-A3B81C77AEE4Q48136353-0EC09482-0230-4D15-B451-8A2F319B8D6EQ51006855-F4215FFC-EEC5-4F9F-82A8-65CA972F9BF3Q55148734-679ACC25-3154-4835-83D6-3BEBE8D97FA7Q55231659-B0D95DC0-E7B5-455B-AF15-F52209BF8307Q57112384-C2E6F220-FAF8-4404-AF3F-579A059C8C5BQ58796089-EABF248A-FE68-434E-8F3A-B2E8ED398FBE
P2860
²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
²¹³Bi-DOTATOC receptor-targete ...... n: a first-in-human experience
@ast
²¹³Bi-DOTATOC receptor-targete ...... n: a first-in-human experience
@en
type
label
²¹³Bi-DOTATOC receptor-targete ...... n: a first-in-human experience
@ast
²¹³Bi-DOTATOC receptor-targete ...... n: a first-in-human experience
@en
prefLabel
²¹³Bi-DOTATOC receptor-targete ...... n: a first-in-human experience
@ast
²¹³Bi-DOTATOC receptor-targete ...... n: a first-in-human experience
@en
P2093
P2860
P1476
²¹³Bi-DOTATOC receptor-targete ...... n: a first-in-human experience
@en
P2093
A Morgenstern
C Apostolidis
C Kratochwil
F Bruchertseifer
F L Giesel
U Haberkorn
P2860
P2888
P304
P356
10.1007/S00259-014-2857-9
P50
P577
2014-07-29T00:00:00Z